CD274 and non-small cell lung carcinoma: A recent study assessed the economic outcomes of atezolizumab versus platinum-based chemotherapy for first-line treatment of EGFR and ALK wild-type metastatic NSCLC in a group with high, high or intermediate PD-L1 expression and in any group with PD-L1 expression from a Chinese health authority perspective, based on the IMpower110 trial.